Nexium Control (Esomeprazole)

Esomeprazole, the active ingredient in Nexium Control, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal conditions such as gastro‑esophageal reflux disease and Zollinger‑Ellison syndrome.

GNH USA supplies Nexium Control as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexium Control, a proton pump inhibitor, is used to treat several acid‑related gastrointestinal disorders. - Gastro‑esophageal reflux disease (GERD): reduces acid exposure and relieves heartburn and regurgitation. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - NSAID‑induced gastric ulcer: protects the gastric mucosa by lowering acid secretion. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Adverse reactions may occur with esomeprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional and self‑limiting. - Abdominal pain: mild discomfort in the upper abdomen.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Hypomagnesemia: low serum magnesium levels that may cause muscle cramps or cardiac arrhythmia. - Interstitial nephritis: inflammation of kidney tissue presenting with reduced urine output or flank pain.

Before initiating therapy, consider the following precautions. - Renal impairment: adjust use in patients with severe kidney disease. - Hepatic impairment: monitor liver function in those with significant liver disease. - Long‑term use: assess need for periodic evaluation of vitamin B12 levels. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Esomeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole: reduced absorption leading to loss of antifungal efficacy. - Atazanavir: markedly decreased plasma concentrations, compromising HIV treatment.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in anticoagulant effect; monitor INR. - Digoxin: modest increase in serum levels; observe for toxicity signs. - Clopidogrel: reduced activation may diminish antiplatelet activity; consider alternative therapy.